Istiratumab  (Synonyms: 艾司妥单抗; MM 141; MM-005)

Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Istiratumab (500 nM，24 小时) 在人胰腺癌细胞系中抑制 IGF-1 和 HRG 共刺激引起的AKT 激活^[2]。
Istiratumab (500 nM，24 小时) 抑制具有激活 KRAS 突变的胰腺癌细胞中 IGF-1 和 HRG 诱导的 AKT 磷酸化^[2]。
Istiratumab (500 nM, 24 h) 通过蛋白酶体途径诱导 IGF-1R 和 ErbB3 受体降解^[2]。
Istiratumab (1 μM，60 分钟) 阻断卵巢癌细胞系中 PI3K 和 MAPK 信号级联的激活^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1509928-04-4

艾司妥单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-lambda]2

• [1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87.  [Content Brief]

  [2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885.  [Content Brief]

  [3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832.  [Content Brief]